NCT07901569Not yet recruiting
Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma
HABITAT: Habitat Analysis of Tumor Thrombus Boundary for Invasion Assessment With Transcriptomic Analysis of Tissue - a Diagnostic Accuracy and Spatial Transcriptomic Validation Study in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Tumor thrombus in the inferior vena cava can invade the vessel wall. Doctors must know the invasion status before surgery. The status changes the surgical plan. Preoperative imaging has limited accuracy for wall invasion. Habitat imaging divides a tumor into subregions. Each subregion is a habitat. The method uses voxel-level image features. This study will test whether habitat imaging can diagnose inferior vena cava wall invasion. The participants have renal cell carcinoma with renal vein or inferior vena cava tumor thrombus. The study will use existing preoperative contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) images. The reference standard is the pathology report from surgery. The primary measurement is the area under the receiver operating characteristic curve (AUROC) of the habitat model for wall invasion. The study will also measure sensitivity, specificity, calibration, and clinical utility. In an exploratory analysis, the study will compare imaging habitats with spatial transcriptomic regions. The study will use available Visium data from two participants. This is a retrospective observational study. The study has no intervention. The study will not change clinical care. The results will show whether habitat imaging can support preoperative planning.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 273 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Liu Zhuo
- Diseases
- Kidney cancer
- NCT number
- NCT07901569
What you commit to
- Study type: Observational
- Planned participants: 273
- From 30 Nov 2026 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The surgical pathology report is missing. The report does not state the wall invasion status.
Other illness
- The reader cannot delineate the tumor thrombus on the image. The study team will report this case as an independent failure reason. The team will not merge this case with missing data.
Other
- The pathology report shows a non-renal-cell-carcinoma histology. Examples are urothelial carcinoma, renal pelvic carcinoma, angiomyolipoma, and adrenocortical carcinoma.
- The preoperative contrast-enhanced CT/MRI image is missing or not adequate. Examples are no contrast phase, severe artifact, or no segmentable image.
Who the study is looking for
- The participant is 18 years or older at surgery.
- The participant had radical nephrectomy with tumor thrombectomy at the study center.
- The participant had renal cell carcinoma with renal vein or inferior vena cava tumor thrombus.
- The pathology report confirms renal cell carcinoma. Any histological subtype is eligible.
- The participant has a preoperative contrast-enhanced computed tomography (CT) or MRI image. The CT/MRI phase is complete. The image has no severe artifact that prevents segmentation.
- The participant has a surgical pathology report. The report states the inferior vena cava wall invasion status.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.